Thongprayoon Charat, Khoury Nadeen J, Bathini Tarun, Aeddula Narothama Reddy, Boonpheng Boonphiphop, Lertjitbanjong Ploypin, Watthanasuntorn Kanramon, Leeaphorn Napat, Chesdachai Supavit, Torres-Ortiz Aldo, Kaewput Wisit, Bruminhent Jackrapong, Mao Michael A, Cheungpasitporn Wisit
Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, USA.
Department of Medicine, Division of Nephrology, Henry Ford Hospital, Detroit, Michigan, USA.
Urol Ann. 2020 Jul-Sep;12(3):241-247. doi: 10.4103/UA.UA_89_19. Epub 2020 Jun 10.
Persistent anemia has been described in kidney transplant (KTx) recipients with parvovirus B19 virus infection. However, the epidemiology of parvovirus B19 and parvovirus B19-related anemia after KTx remains unclear. We conducted this systematic review (1) to investigate the incidence of parvovirus B19 infection after KTx and (2) to assess the incidence of parvovirus B19 among KTx patients with anemia.
A systematic review was conducted in EMBASE, MEDLINE, and Cochrane databases from inception to March 2019 to identify studies that reported the incidence rate of parvovirus B19 infection and/or seroprevalence of parvovirus B19 in KTx recipients. Effect estimates from the individual studies were extracted and combined using random-effects, generic inverse variance method of DerSimonian and Laird. The protocol for this systematic review is registered with PROSPERO (no. CRD42019125716).
Nineteen observational studies with a total of 2108 KTx patients were enrolled. Overall, the pooled estimated seroprevalence of parvovirus B19 immunoglobulin G was 62.2% (95% confidence interval [CI]: 45.8%-76.1%). The pooled estimated incidence rate of positive parvovirus B19 DNA in the 1 year after KTx was 10.3% (95% CI: 5.5%-18.4%). After sensitivity analysis excluded a study that solely included KTx patients with anemia, the pooled estimated incidence rate of positive parvovirus B19 DNA after KTx was 7.6% (95% CI: 3.7%-15.0%). Among KTx with anemia, the pooled estimated incidence rate of positive parvovirus B19 DNA was 27.4% (95% CI: 16.6%-41.7%). Meta-regression analysis demonstrated no significant correlations between the year of study and the incidence rate of positive parvovirus B19 DNA ( = 0.33). Egger's regression asymmetry test was performed and demonstrated no publication bias in all analyses.
The overall estimated incidence of positive parvovirus B19 DNA after KTX is 10.3%. Among KTx with anemia, the incidence rate of positive parvovirus B19 DNA is 27.4%. The incidence of positive parvovirus B19 DNA does not seem to decrease overtime.
肾移植(KTx)受者感染细小病毒B19后会出现持续性贫血。然而,KTx后细小病毒B19及与细小病毒B19相关贫血的流行病学仍不清楚。我们进行了这项系统评价,(1)以调查KTx后细小病毒B19感染的发生率,(2)评估贫血的KTx患者中细小病毒B19的发生率。
在EMBASE、MEDLINE和Cochrane数据库中进行了一项系统评价,检索时间从建库至2019年3月,以确定报告KTx受者中细小病毒B19感染发生率和/或细小病毒B19血清阳性率的研究。提取各研究的效应估计值,并使用DerSimonian和Laird的随机效应、通用逆方差法进行合并。本系统评价的方案已在PROSPERO注册(编号CRD42019125716)。
纳入了19项观察性研究,共2108例KTx患者。总体而言,细小病毒B19免疫球蛋白G的合并估计血清阳性率为62.2%(95%置信区间[CI]:45.8%-76.1%)。KTx后1年内细小病毒B19 DNA阳性的合并估计发生率为10.3%(95%CI:5.5%-18.4%)。敏感性分析排除一项仅纳入贫血KTx患者的研究后,KTx后细小病毒B19 DNA阳性的合并估计发生率为7.6%(95%CI:3.7%-15.0%)。在贫血的KTx患者中,细小病毒B19 DNA阳性的合并估计发生率为27.4%(95%CI:16.6%-41.7%)。Meta回归分析显示研究年份与细小病毒B19 DNA阳性发生率之间无显著相关性( = 0.33)。进行了Egger回归不对称检验,结果表明所有分析均无发表偏倚。
KTx后细小病毒B19 DNA阳性的总体估计发生率为10.3%。在贫血的KTx患者中,细小病毒B19 DNA阳性的发生率为27.4%。细小病毒B19 DNA阳性的发生率似乎不会随时间下降。